New injection aims to control rare genetic liver disease
NCT ID NCT06247670
First seen May 02, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This early-stage study tests a new drug, CMP-CPS-001, given as a shot under the skin. It includes 120 healthy adults and people with a genetic condition called OTC deficiency, which affects the liver's ability to remove ammonia from the body. The main goal is to check safety and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OTC DEFICIENCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Erasmus MC
Rotterdam, Netherlands
-
Nucleus Network Brisbane (also known as Q-Pharm Pty Ltd)
Herston, Queensland, Australia
Conditions
Explore the condition pages connected to this study.